AR059356A1 - Nuevos radioligandos - Google Patents

Nuevos radioligandos

Info

Publication number
AR059356A1
AR059356A1 ARP070100511A ARP070100511A AR059356A1 AR 059356 A1 AR059356 A1 AR 059356A1 AR P070100511 A ARP070100511 A AR P070100511A AR P070100511 A ARP070100511 A AR P070100511A AR 059356 A1 AR059356 A1 AR 059356A1
Authority
AR
Argentina
Prior art keywords
radioligands
new
compound
receptor
brain
Prior art date
Application number
ARP070100511A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR059356A1 publication Critical patent/AR059356A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente se refiere a nuevos radioligandos para el receptor 5-HT1B (receptor dopaminérgico). Estos compuestos pueden ser utilizados para monitorear la depresion en humanos mediante la medicion de la distribucion espacial de dicho compuesto en el cerebro. Reivindicacion 1: Un compuesto isotopicamente marcado de la formula 1, o una sal farmacéuticamente aceptable del mismo, donde el compuesto comprende al menos una marca isotopica seleccionada de 3H, 11C, 13N o 15O.
ARP070100511A 2006-02-14 2007-02-07 Nuevos radioligandos AR059356A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77330206P 2006-02-14 2006-02-14

Publications (1)

Publication Number Publication Date
AR059356A1 true AR059356A1 (es) 2008-03-26

Family

ID=38371808

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100511A AR059356A1 (es) 2006-02-14 2007-02-07 Nuevos radioligandos

Country Status (8)

Country Link
US (1) US20090004106A1 (es)
EP (1) EP1987017A4 (es)
JP (1) JP2009532328A (es)
CN (1) CN101384578A (es)
AR (1) AR059356A1 (es)
TW (1) TW200804363A (es)
UY (1) UY30146A1 (es)
WO (1) WO2007094718A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
EP2247558B2 (en) * 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
CA2731738A1 (en) 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
US8617517B2 (en) * 2009-01-29 2013-12-31 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010111303A2 (en) 2009-03-23 2010-09-30 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
EP2655365B1 (en) 2010-12-20 2015-12-16 Acturum Life Science AB 2-carboxamide-4-piperazinyl-benzofuran derivative
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
JP2021529771A (ja) 2018-07-02 2021-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリンナトリウムおよびα−ラクトースの粉末製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353915A2 (en) * 2001-01-16 2003-10-22 AstraZeneca AB Therapeutic chroman compounds
IL156595A0 (en) * 2001-01-16 2004-01-04 Astrazeneca Ab Therapeutic heterocyclic compounds
JP2004517129A (ja) * 2001-01-16 2004-06-10 アストラゼネカ・アクチエボラーグ 治療用クロモン化合物
AU2002336749A1 (en) * 2001-09-21 2003-04-01 Pharmacia And Upjohn Company Tricyclic indole derivatives as 5-ht ligands
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
EP1485386A2 (en) * 2002-03-04 2004-12-15 PHARMACIA & UPJOHN COMPANY Pyridinyloxy derivatives as 5-ht receptor ligands

Also Published As

Publication number Publication date
US20090004106A1 (en) 2009-01-01
UY30146A1 (es) 2007-09-28
CN101384578A (zh) 2009-03-11
WO2007094718A1 (en) 2007-08-23
TW200804363A (en) 2008-01-16
EP1987017A4 (en) 2010-08-25
EP1987017A1 (en) 2008-11-05
JP2009532328A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
AR059356A1 (es) Nuevos radioligandos
NI201100016A (es) Formulaciones farmacéuticas que contienen ligandos de receptores de dopamina.
CL2011000237A1 (es) Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.
ES2567159T3 (es) Método para la deshidratación de alcoholes grasos
NI201400121A (es) Compuestos de indol e indazol que activan la ampk
CR10674A (es) Inhibidores de la metaloproteinasa matriz
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
GT200600030A (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2
AR077292A1 (es) Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
ECSP11011398A (es) Inhibidores de beta-secretasa
HN2010002772A (es) Compuestos organicos nuevo titulo de la invencion: derivados de 2-(3-piridil)-indol sustituido y composicionesfarmaceuticas de los mismos. (bajo el escrito 2013-000513 de fecha 27 de febrero de 2013) solicitado por esta oficina de registro
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
CO6220968A2 (es) Inhibidores heterociclicos de la aspartil proteasa
MA30950B1 (fr) Nouveaux (aza) cyclohexanes carbonyles en tant que ligands du recepteur de dopamine d3.
ES2380489T8 (es) Proceso para la síntesis de compuestos orgánicos
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
PA8840901A1 (es) Nuevo procedimiento de resolución de enantiómeros de (3,4-dimetoxi-biciclo[4.2.0]octa-1,3,5-trien-7-il, aplicación en la sistesis de ivabradina
GT200600117A (es) Nuevos compuestos farmaceuticos
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
AR074379A1 (es) Inhibidor de triazolotiadiazola de la proteina quinasa c-met
UY31460A1 (es) Procedimiento de preparacion de compuestos morfinicos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal